Scientific deep-dive
Does Wegovy Cause Fatigue? Label Rates, Mechanism & Management Evidence
Wegovy (semaglutide 2.4 mg) fatigue is a listed FDA adverse reaction: the label reports ~11% on semaglutide vs ~5% on placebo across its pooled trials. Caloric deficit is the load-bearing mechanism. Timeline, labs to check, hydration + protein protocol, and Zepbound comparison.
The honest answer:
Yes, Wegovy (semaglutide 2.4 mg) can cause fatigue. The Wegovy FDA prescribing information Section 6.1 lists fatigue (including asthenia) at roughly 11% on semaglutide 2.4 mg versus 5% on placebo, pooled across three placebo-controlled trials in adults with obesity or overweight, STEP-1 among them[6]. The drug-attributable rate is about 6 percentage points, or roughly 1 in 17 patients. Most Wegovy fatigue is titration-related, peaks in the first 1–2 weeks after each dose escalation, and resolves within 2–4 weeks at a stable dose. The load-bearing mechanism is the caloric deficit the drug produces; secondary drivers are dehydration from GI side effects, glucose fluctuations in combination therapy, and possible micronutrient gaps in long-term users.
“Wegovy fatigue” is one of the most-searched practical questions on semaglutide for obesity. The honest answer involves four things: how often it actually happened in the Phase 3 STEP program, what the published literature supports as the mechanism, how to tell ordinary titration tiredness from something that needs a lab workup, and the practical day-to-day management that resolves the vast majority of cases without changing the Wegovy regimen. This article walks through the pooled adverse-reaction table in Wegovy FDA label Section 6.1 (three placebo-controlled trials including STEP-1), the corroborating data from STEP-2 (type 2 diabetes), STEP-4 (maintenance), and SELECT (cardiovascular-disease population), the comparison to tirzepatide’s SURMOUNT-1 fatigue rate, the mechanism candidates that the published evidence supports, and the labs-and-lifestyle protocol used in clinical practice.
What the Wegovy FDA label says about fatigue
The Wegovy DailyMed prescribing information[6] Section 6.1 (Clinical Trials Experience) reports adverse reactions pooled across three randomized, placebo-controlled trials that included 2,116 adults with obesity or overweight treated with 2.4 mg. Fatigue (defined to include fatigue and asthenia) appears at approximately 11% on semaglutide 2.4 mg versus 5% on placebo — a drug-attributable rate of roughly 6 percentage points, or about 1 in 17 patients above background.
That is a meaningful signal but not the dominant safety signal on Wegovy. The same Section 6.1 table reports nausea at roughly 44% on semaglutide 2.4 mg, diarrhea at 30%, vomiting at 24%, and constipation at 24%. The gastrointestinal cluster is the dominant tolerability story on Wegovy; fatigue is a secondary signal that, while real, rarely rises to the level of being the primary reason a patient discontinues therapy. The label classifies fatigue as a “most common adverse reaction” (occurring in ≥5% of patients and more frequently than placebo) but not as a serious adverse reaction.
What the STEP trials reported about fatigue
STEP-1[1] was the Phase 3 pivotal trial that supported the FDA approval of Wegovy for chronic weight management. It randomized 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity, excluding diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks, with a 16-week titration schedule (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, 4 weeks per step). Its safety data feed the Wegovy prescribing information, where the fatigue rate is reported pooled with two other placebo-controlled trials rather than for STEP-1 alone[6].
The headline efficacy result was a mean weight loss of 14.9% on semaglutide 2.4 mg versus 2.4% on placebo at 68 weeks — a magnitude that requires a sustained, substantial caloric deficit. The pooled placebo fatigue rate in the label (~5%)[6] reflects the background rate of fatigue in adults with obesity over a 68-week observation window, meaning a substantial fraction of the fatigue patients attribute to Wegovy would have occurred anyway. The drug-attributable share at the 2.4 mg maintenance dose is the ~6 percentage points above placebo.
Does the signal hold up in the other STEP and SELECT trials?
STEP-1 is one trial. The strongest evidence for a real drug-related adverse-event signal is replication across independent trials in different populations. Semaglutide 2.4 mg has now been studied in four major datasets relevant to Wegovy: STEP-1 (general obesity)[1], STEP-2 (overweight/obesity with type 2 diabetes)[2], STEP-4 (maintenance after a 20-week run-in)[3], and SELECT (overweight/obesity plus established cardiovascular disease, mean follow-up 39.8 months)[4]. Across all four, the published adverse-event profiles share the same signature: gastrointestinal events dominate. Trial-specific fatigue rates are not reported in their abstracts; the 11% figure comes from the Wegovy label’s pooled table of three STEP trials[6].
STEP-4[3] is particularly informative because it directly tests the question of whether fatigue persists past titration. The trial used a 20-week open-label run-in (during which all participants titrated up to 2.4 mg) followed by a 48-week randomized maintenance phase where participants were re-randomized to continue semaglutide 2.4 mg or switch to placebo. The adverse-event burden during the maintenance phase was lower than during the titration run-in, supporting the clinical pattern that most Wegovy fatigue is titration-related rather than persistent at a stable dose.
SELECT[4] is the largest and longest-duration Wegovy safety dataset published to date: 17,604 adults with overweight or obesity and prior cardiovascular disease, followed for a mean of 39.8 months. The trial established a 20% relative risk reduction in major adverse cardiovascular events on semaglutide 2.4 mg versus placebo, and the safety profile over the multi-year observation window remained consistent with the STEP program — the gastrointestinal cluster dominated, and there was no evidence of a late-onset fatigue signal beyond what was already documented in STEP-1. Adverse events leading to permanent discontinuation occurred in 16.6% of semaglutide patients versus 8.2% on placebo, with gastrointestinal disorders as the leading driver.
Mechanism — GI cascade, dehydration, rapid weight loss
The published literature does not establish a single drug-receptor pathway for semaglutide-related fatigue. The mechanism is most plausibly multifactorial, with four candidate drivers that map onto the clinical pattern patients describe. The first is load-bearing — it explains the majority of the fatigue burden by itself.
1. The caloric deficit (load-bearing)
Wegovy works in part by dramatically reducing food intake. STEP-1[1] participants on semaglutide 2.4 mg lost approximately 14.9% of body weight over 68 weeks — a magnitude that requires a sustained, substantial caloric deficit. During the first weeks of each titration step, the appetite-suppressing effect intensifies before the body adapts its metabolic rate. Patients are simply running on fewer calories than they were habituated to. This produces the same low-grade fatigue, reduced exercise capacity, and general energy gap seen in any setting of acute caloric restriction — bariatric surgery recovery, very-low-calorie diets, prolonged fasting. The fatigue feels drug-related but the mechanism is the deficit itself, and it resolves as the body adapts to the new intake level (typically within 2–4 weeks of each escalation step).
This mechanism is self-limiting and is the primary reason Wegovy fatigue is not a long-term complaint for most patients: by the time someone reaches the 2.4 mg maintenance dose and a stable weight, the deficit-driven energy gap has resolved. The clinical implication is to slow titration and protect protein intake (see management section), not to discontinue the drug.
2. Dehydration from the GI cascade and blunted thirst
Nausea (~44% in pooled STEP data)[6], vomiting (~24%), and diarrhea (~30%) directly reduce fluid intake and increase fluid loss. Layered on top of that, semaglutide acts on central GLP-1 receptor populations that overlap with hypothalamic circuits regulating both hunger and thirst. In the first weeks of therapy, patients commonly describe reduced spontaneous thirst alongside reduced spontaneous hunger. The combined result is mild chronic underhydration. Even a 1–2% body-water deficit is a well-established cause of fatigue, reduced cognitive performance, and physical weakness. The Wegovy DailyMed label[6] specifically warns that dehydration from GI side effects has been associated with postmarketing acute kidney injury cases — the same hydration deficit is the leading non-deficit driver of titration-phase fatigue.
3. Glucose fluctuations — mostly a combination-therapy issue
Semaglutide is a glucose-dependent insulin secretagogue and improves glycemic control. In monotherapy in adults without diabetes, clinically significant hypoglycemia is uncommon. The clinically important exception is patients taking Wegovy alongside insulin or a sulfonylurea (relevant for the subset of patients with comorbid type 2 diabetes — the population studied in STEP-2[2]), where hypoglycemia rates rise sharply and the Wegovy label[6] specifies that the concomitant insulin or sulfonylurea dose should be reduced when starting Wegovy. Hypoglycemic fatigue is real, can escalate into a medical emergency, and is one of the few situations in which a Wegovy fatigue episode is an early warning sign of a more serious underlying event. Patients on combination therapy who develop fatigue plus sweating, tremor, confusion, or rapid heartbeat should check blood glucose before attributing the episode to “just the Wegovy.”
4. Micronutrient gaps in long-term users
Long-term reduced food intake produces lower intake of B12-rich foods (meat, fish, dairy, eggs), iron-rich foods, and the calorie-dense sources of vitamin D and other micronutrients. This is not a drug-attributable adverse reaction listed on the Wegovy label — it is a downstream consequence of sustained caloric restriction that any chronic-weight-management intervention can produce. Patients on Wegovy for >6 months who develop persistent fatigue at a stable dose should have a basic lab workup (ferritin, vitamin D 25-OH, vitamin B12, TSH, and a CBC for anemia) before assuming the fatigue is drug-direct. Iron deficiency in particular is the single most-replicated non-thyroid driver of persistent fatigue in adults, and is common in adults with obesity at baseline.
Timeline — when fatigue starts and when it resolves
Wegovy uses a 16-week monthly titration ladder: 0.25 mg (weeks 1–4) → 0.5 mg (weeks 5–8) → 1.0 mg (weeks 9–12) → 1.7 mg (weeks 13–16) → 2.4 mg (weeks 17+). Fatigue tends to onset within the first 1–2 weeks after each dose increase, peak at week 1–2 post-escalation, and resolve within 2–4 weeks as the body adapts to the new dose. The 0.25 mg starting dose is intentionally sub-therapeutic for weight loss — it exists to introduce the drug at a tolerable level, and most patients experience minimal fatigue at this step. Escalation steps from 0.5 mg upward are where most fatigue reports cluster, with the largest jump (1.0 mg → 1.7 mg or 1.7 mg → 2.4 mg) being the most likely titration step to trigger a reset of the tiredness pattern.
- Weeks 1–4 (0.25 mg starter): mild fatigue if any; most patients adapt within days.
- Weeks 5–8 (0.5 mg): first step where appetite suppression becomes noticeable; caloric deficit begins to drive a small energy gap in some patients.
- Weeks 9–12 (1.0 mg): the same dose used for type 2 diabetes management in Ozempic; fatigue reports are common but typically mild.
- Weeks 13–16 (1.7 mg): a sub-maximal step unique to Wegovy; meaningful weight loss is usually occurring by this point.
- Weeks 17+ (2.4 mg maintenance): full therapeutic dose. The label's pooled trial data show approximately 11% fatigue versus 5% placebo at this dose — the drug-attributable rate of ~6 percentage points.
- Beyond 4 weeks at the 2.4 mg maintenance dose: persistent fatigue is not expected and warrants the labs-and-lifestyle workup in the next section.
Patients sometimes experience the fatigue pattern resetting with each new escalation step — feeling fine at 0.5 mg, then tired again for 1–2 weeks after moving to 1.0 mg. This is the expected pattern, not a sign that Wegovy “is not working” or that fatigue will be permanent. The right clinical response is to stay at a current dose for an extra 4 weeks rather than escalate on schedule if the tiredness is interfering with daily function.
How Wegovy fatigue compares to Zepbound, Mounjaro, and Ozempic
SURMOUNT-1[5] is the parallel pivotal trial for tirzepatide 15 mg, the active ingredient in Zepbound. The Zepbound FDA prescribing information Section 6.1, pooling two weight-reduction trials that include SURMOUNT-1, reports fatigue (defined to include asthenia, fatigue, lethargy, and malaise) at 5% at 5 mg, 6% at 10 mg, and 7% at 15 mg versus 3% on placebo. At face value, the maximum-dose tirzepatide fatigue rate (7%) is lower than the Wegovy 2.4 mg rate (~11%). The drug-attributable share is roughly 4 percentage points on Zepbound versus 6 on Wegovy.
Before treating that as a meaningful Wegovy-vs-Zepbound ranking, the cross-trial comparison requires extreme caution. STEP-1 and SURMOUNT-1 enrolled overlapping but non-identical populations, used different titration schedules (5-step semaglutide vs 6-step tirzepatide), ran for different durations (68 weeks vs 72 weeks), and ascertained adverse events with different footnote definitions for the fatigue category. The Zepbound footnote (“includes asthenia, fatigue, lethargy, and malaise”) is broader than the Wegovy footnote (“includes fatigue and asthenia”), which would, all else equal, push the Zepbound number higher than the Wegovy number on a like-for-like basis — not lower. No head-to-head randomized trial has compared fatigue incidence between semaglutide and tirzepatide as a primary or secondary endpoint in obesity populations. Patients evaluating the two drugs should not use fatigue as a tiebreaker.
Mounjaro (tirzepatide for type 2 diabetes) and Ozempic (semaglutide for type 2 diabetes, 0.5–2.0 mg, lower than the Wegovy 2.4 mg dose) share the same active ingredients as Zepbound and Wegovy respectively, but the diabetes-indication adverse-event tables reflect different patient populations (older, comorbidity-burdened, often on background diabetes medications). The Ozempic DailyMed label only lists fatigue among other adverse reactions with a frequency above 0.4%, without a per-dose rate. The Wegovy label does show a dose relationship: in its two 7.2 mg trials, fatigue was 9% on 2.4 mg and 11% on 7.2 mg versus 5% on placebo[6].
Magnitude comparison
Trial-reported fatigue rates at the top trial dose — semaglutide 2.4 mg in the Wegovy label's pooled trials, including STEP-1 (Wegovy active ingredient) vs tirzepatide 15 mg in the Zepbound label's two pooled trials, including SURMOUNT-1 (Zepbound active ingredient), against placebo rates from each label table. Cross-trial comparisons are suggestive, not conclusive: no head-to-head trial; fatigue-definition footnotes differ between labels.[1][5][6]
- Semaglutide 2.4 mg (pooled label trials, up to 68 wk)11 %Wegovy maintenance dose
- Tirzepatide 15 mg (label, 2 pooled trials)7 %Zepbound maximum dose
- Tirzepatide 10 mg (label, 2 pooled trials)6 %
- Placebo (pooled Wegovy label trials)5 %background rate in obesity over 68 wk
- Tirzepatide 5 mg (label, 2 pooled trials)5 %
- Placebo (Zepbound label, 2 pooled trials)3 %
When fatigue is a red flag (anemia, B12, thyroid, depression)
Persistent fatigue at a stable Wegovy dose is the clinical scenario where the question shifts from “is this Wegovy?” to “what else might be going on that the Wegovy is making more visible?” A patient who has been at 2.4 mg for more than 4–8 weeks and remains meaningfully fatigued should not be assumed to have drug-attributable fatigue without ruling out the standard primary-care differential:
- Iron-deficiency anemia. Ferritin and a CBC rule out the single most-replicated non-thyroid driver of persistent adult fatigue. Iron deficiency is common in adults with obesity at baseline and can be worsened by sustained reduced intake of iron-rich foods on Wegovy.
- Vitamin B12 deficiency. Reduced dietary intake of meat/fish/dairy/eggs over months can drive B12 stores down. Especially relevant if the patient is also on metformin (which independently reduces B12 absorption) or follows a predominantly plant-based diet.
- Vitamin D deficiency. Common in obesity from volumetric dilution into adipose tissue, and the supplementation response is well-documented. A 25-OH vitamin D level closes this differential.
- Hypothyroidism. A TSH rules this out. Both unrecognized hypothyroidism and Hashimoto’s thyroiditis are more prevalent in adults with obesity.
- Depression or sleep-disordered breathing. Both can present as physical fatigue with no other obvious driver. PHQ-9 screening plus a sleep history (snoring, witnessed apneas, daytime somnolence) is appropriate.
- Poor glycemic control (in T2D patients). Fasting glucose plus HbA1c. Both undiagnosed diabetes and poor control in known diabetics on combination therapy can present as fatigue.
None of these labs are part of the Wegovy monitoring requirements in the prescribing information[6] — they are part of the standard primary-care fatigue workup that a prescriber would order for any patient with persistent unexplained fatigue. The Wegovy context just shifts the threshold for ordering them sooner, because the medication creates a plausible alternative explanation that can mask a real underlying deficiency for months.
Practical management — hydration, electrolytes, sleep, exercise pairing
The clinical management pattern for Wegovy titration-phase fatigue is conservative and stepwise. None of these steps requires changing the Wegovy regimen for most patients.
Protein intake adequacy
Protein is the single most important nutritional lever for managing fatigue and preserving lean mass during rapid weight loss on Wegovy. Aim for 1.2–1.6 g protein per kg of lean body mass per day, distributed across 3–4 meals/snacks. Protein has the highest satiety value per calorie (helpful when total intake is low), stabilizes blood glucose more effectively than carbohydrate-dominant meals (reducing post-meal energy crashes), and protects against the lean-mass loss that accompanies any rapid weight reduction. Practical protein anchors: 25–40 g per meal from eggs, Greek yogurt, fish, poultry, legumes, tofu, or whey protein. A small high-protein snack is often better tolerated than a full meal during periods of GLP-1-induced nausea.
Active hydration with electrolytes
Target 64–80 oz (2–2.5 L) of fluid per day, tracked rather than estimated. Set timed reminders if necessary. Plain water counts. Sugary drinks should be limited because they trade hydration for caloric load. During active GI symptoms (nausea, vomiting, diarrhea), oral rehydration salts (the WHO formulation or commercial equivalents like Liquid IV, LMNT, or Pedialyte) are preferable to plain water — plain-water rehydration in the setting of GI losses can produce dilutional hyponatremia, which is itself a fatigue trigger.
Sleep hygiene
Poor sleep amplifies perceived fatigue on Wegovy. Common sleep disruptors during titration include nighttime nausea, late-evening GI discomfort, and (in combination-therapy patients) nocturnal hypoglycemia. Practical adjustments:
- Inject Wegovy in the morning rather than at bedtime to shift the nausea peak away from sleep hours.
- Avoid large meals within 3 hours of sleep — slowed gastric emptying worsens when lying down.
- If you wake with sweating or anxiety, check blood glucose if you are on insulin or a sulfonylurea — this is the classical nocturnal hypoglycemia presentation.
Exercise pairing — light is the right dose during titration
Exercise during the early titration weeks should be paced to the energy budget the deficit allows, not to a pre-Wegovy baseline. Push too hard while the body is adapting to the new calorie level and the result is amplified fatigue, not better outcomes. Walking, light resistance training to preserve lean mass, and stretching tolerate the deficit well; high-intensity interval training and long endurance sessions typically don’t. Once a maintenance dose and stable weight are reached, exercise capacity returns toward baseline within 4–8 weeks for most patients.
Slow titration if fatigue is dose-limiting
The FDA-approved Wegovy titration schedule is a minimum, not a requirement. The Wegovy label[6] describes the 4-week escalation interval as the standard, but prescribers can hold patients at any dose level for additional weeks if tolerability is a concern. Patients experiencing significant fatigue or nausea at a given dose can ask their prescriber to extend the current dose period before the next escalation. Slower titration reduces peak plasma-level changes and gives the body more time to adapt. An extra 4 weeks at 1.0 mg or 1.7 mg is almost always the right move over pushing through active fatigue.
When to call your prescriber
Seek urgent or emergency care for any of:
- Fatigue with blood glucose below 70 mg/dL or symptoms consistent with hypoglycemia (sweating, tremor, confusion, rapid heartbeat, vision changes) that do not resolve with oral glucose — especially in patients on concomitant insulin or a sulfonylurea.
- Inability to keep fluids down for more than 24 hours — severe vomiting preventing oral hydration can rapidly progress to dehydration requiring IV fluids.
- Dark urine and markedly reduced urination — signs of significant dehydration or kidney stress. The Wegovy label[6] specifically warns about postmarketing acute kidney injury cases following dehydration from GI side effects.
- Severe generalized weakness — difficulty standing or walking that is out of proportion to typical tiredness.
- Fainting or near-fainting (syncope) — can indicate hypoglycemia, severe dehydration, or orthostatic hypotension from over-aggressive antihypertensives that have become relatively excessive as systolic pressure drops with weight loss.
- Chest pain, shortness of breath, or rapid irregular heartbeat — requires immediate evaluation regardless of Wegovy status. See our Wegovy heart palpitations evidence review for the cardiac-symptom context.
- Confusion, difficulty speaking, or sudden severe cognitive changes — can indicate severe hypoglycemia, particularly in patients on insulin or sulfonylurea.
- Fatigue persisting beyond 4–8 weeks at the 2.4 mg maintenance dose — not an emergency, but warrants the lab workup described above plus a prescriber check-in. Do not assume persistent stable-dose fatigue is “just the Wegovy.”
Practical takeaway
- Fatigue is real but secondary. ~11% on semaglutide 2.4 mg vs ~5% on placebo in the label's pooled trials. The drug-attributable rate is roughly 6 percentage points. Not the dominant safety signal — the GI cluster is.
- Mechanism is plausibly multifactorial, with the caloric deficit load-bearing. Dramatically reduced food intake produces a temporary energy gap that resolves as the body adapts. Secondary drivers: dehydration from GI symptoms and blunted thirst drive, glucose fluctuations in combination therapy with insulin or sulfonylurea, and long-term micronutrient gaps. No single drug-receptor pathway has been established.
- Timeline tracks the titration ladder. Fatigue peaks 1–2 weeks after each escalation step and resolves within 2–4 weeks at a stable dose. The pattern resets with each new dose increase. Persistent fatigue beyond 4–8 weeks at the 2.4 mg maintenance dose is not expected.
- First-line management is protein + hydration + sleep + slower titration. Target 1.2–1.6 g protein per kg lean body mass per day, 64–80 oz tracked fluid intake, morning rather than bedtime dosing, and an extra 4 weeks at a tolerated dose rather than pushing through escalation. Most titration fatigue resolves with these adjustments alone.
- Lab workup when fatigue persists. Ferritin, vitamin D 25-OH, B12, TSH, and a CBC are the standard differential-diagnosis labs. Iron deficiency in particular is the most-replicated non-thyroid driver of persistent adult fatigue.
- Red flags are urgent. Fatigue with hypoglycemia symptoms (especially on combination therapy), inability to keep fluids down for >24 hours, dark urine with reduced output, fainting, severe weakness, or sudden cognitive changes all warrant prescriber contact or emergency evaluation.
- Fatigue should not be the tiebreaker between Wegovy and Zepbound. Cross-trial comparison suggests semaglutide may have a modestly higher fatigue rate (~11% vs ~7%), but the comparison is not head-to-head and the fatigue-definition footnotes differ between labels. Pick on weight-loss magnitude, GI tolerability, dose schedule, cardiovascular benefit, and cost — not on fatigue.
For the operational question of how to titrate through the first weeks of Wegovy without losing tolerability, see our GLP-1 side-effect Q&A hub. For the sister analysis on tirzepatide, see Does Zepbound cause fatigue? SURMOUNT-1 rates, mechanism & management evidence. For the broader Wegovy clinical picture, the Wegovy drug page consolidates pricing, dose tiers, FDA-approved indications, and provider availability.
Further reading
- Top semaglutide side-effect questions on Reddit, answered
- Top semaglutide weight-loss studies (curated PubMed reading list)
- GLP-1 sick-day guide cheat sheet
Our reviews
Providers that offer semaglutide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.9. Read our review of GobyMedsNo-membership, no-auto-renew compounded GLP-1 orders, from about $99/mo on a 3-month bundleFrom$169/mostarting pricecompounded
- Editorial score: 7.8. Read our review of EmbodyLow flat-rate compounded GLP-1 pricing at every doseFrom$79/mosale pricecompounded
- Editorial score: 7.8. Read our review of SnagRxCompounded semaglutide and tirzepatide at a flat lifetime priceFrom$99/mocompounded
- Editorial score: 7.7. Read our review of Live VitalLow-cost, physician-led compounded GLP-1 with peptide and hormone optionsFrom$130/moafter intro offercompounded
- Editorial score: 7.7. Read our review of TrimRxBest overall valueFrom$179/mostarting dosecompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
- 2.Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. PMID: 33667417.
- 3.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
- 4.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131.
- 5.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
- 6.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information. DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Related research
Why Does Tirzepatide / Semaglutide Make You Tired? GLP-1 Fatigue: Onset, Mechanism, and Management
Fatigue is a listed adverse reaction on GLP-1 labels: 11% on Wegovy versus 5% on placebo, and up to 7% on Zepbound at 15 mg versus 3%. Causes include eating too little, dehydration, and low blood sugar. It usually fades within 2 to 4 weeks at a stable dose.
14 min read
Does Wegovy Cause Dizziness? FDA Label, Mechanisms & Management Evidence Review
The Wegovy label reports dizziness in 8% of adults vs 4% on placebo. Likely causes are dehydration from vomiting or diarrhea, low blood pressure on standing as weight drops, and low blood sugar when combined with insulin or a sulfonylurea. What helps and when to call.
13 min read
Does Wegovy Cause Migraines or Headaches? FDA Label & Trial Evidence Review
Wegovy (semaglutide 2.4 mg) FDA label §6.1 reports headache at 14% vs 10% placebo. Migraine is NOT listed on the label. The only migraine signal is a 2025 FAERS class-level reporting ratio of 1.28 — hypothesis-generating, not causal. Dehydration is the load-bearing mechanism.
13 min read
Does Mounjaro Cause Fatigue? FDA Label, SURPASS-1 Data & T2D Hypoglycemia Evidence
Mounjaro (tirzepatide) fatigue is NOT in the FDA Section 6.1 Table 1 (the >=5% AEs are GI events plus decreased appetite). The dominant T2D fatigue driver is hypoglycemia from concomitant insulin or sulfonylurea: BG <54 mg/dL in 14-19% on basal-insulin combination per Table 2.
13 min read
GLP-1 Side Effects Duration: Fatigue, Hair Loss, and How Long Everything Actually Lasts
Most GLP-1 nausea fades within 1 to 2 weeks at each dose step, peaking in the first 1 to 2 weeks after an increase. Fatigue was reported by about 11% on semaglutide versus 5% on placebo in the Wegovy label's pooled STEP 1-3 data. This guide covers how long fatigue, hair loss, and GI effects last.
11 min read
Ozempic Fatigue: Why Semaglutide Can Make You Tired & What to Do (2026)
Is fatigue an Ozempic side effect? Yes — fatigue and asthenia are labeled for semaglutide. Why it happens (under-eating, dehydration, low blood sugar), when tiredness is a red flag, and prescriber-directed ways to manage it. Verified against the FDA DailyMed labels.
9 min read
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →From $129/mo
starting dose
Found
Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s
Read full review →From $169/mo
12-month plan rate
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $200/mo
starting dose